Dr. David Roblin

External Independent Director

David is an experienced scientist and physician, with a distinguished career in the pharmaceutical industry, most notably as Senior Vice President and Head of R&D for Pfizer in Europe. He and his units have brought many medicines in several therapy areas through R&D to successful commercialization.

Most recently, David has served as President of R&D at Summit Therapeutics plc, an international clinical-stage company listed on AIM in the UK and NASDAQ in the US from 2017 to January 2020.

He also served as the Chief Operating Officer and Director of Scientific Translation at the Francis Crick Institute in London from 2014 to 2017. Prior to this, he was Head of Research and Chief Medical Officer for Europe R&D at Pfizer Inc. from 2008 to 2011 and was Head of Therapy Area for Anti-infectives at Bayer AG from 1997 to 1999.

David has a degree in biochemistry from University of London and qualified in Medicine from St George’s Hospital, London. He is a Fellow of the Royal College of Physicians, Fellow of the Faculty of Pharmaceutical Medicine and a Fellow of the Academy of Medical Sciences. He is an honorary Professor of Medicine at Swansea University and Professor of Translational Medicine at St George’s. He also sits on a variety of committees at Wellcome, on the UK Biomedical Catalyst Fund and the LEO Foundation prize committee.

David was elected to the Sosei Group Board of Directors in June 2018.